Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

  • Lorenzo Falchi
  • , Anna Sureda Balari
  • , Sirpa Leppä
  • , Joost S.P. Vermaat
  • , Marcel Nijland
  • , Jacob Haaber Christensen
  • , Sven de Vos
  • , Harald Holte
  • , Reid W Merryman
  • , Pieternella Johanna Lugtenburg
  • , Pau Abrisqueta Costa
  • , Kim M. Linton
  • , Gauri Sunkersett
  • , Christopher Morehouse
  • , Andrew J. Steele
  • , Jennifer Marek
  • , Liwei Wang
  • , Daniela Hoehn
  • , Martin Hutchings
  • , David Belada

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
Artikelnummer342
TidsskriftBlood
Vol/bind144
Udgave nummerSuppl. 1
ISSN0006-4971
DOI
StatusUdgivet - 5. nov. 2024
Begivenhed66th ASH Annual Meeting - San Diego, USA
Varighed: 7. dec. 202410. dec. 2024

Konference

Konference66th ASH Annual Meeting
Land/OmrådeUSA
BySan Diego
Periode07/12/202410/12/2024

Citationsformater